Guiding an Improved Dementia Experience
(GUIDE) Model Aims to Increase Care Coordination, Support for
Caregivers
JACKSONVILLE, Fla., July 9, 2024
/PRNewswire/ -- Today, NeuroX announced they have been selected by
the Centers for Medicare & Medicaid Services (CMS) to
participate in a new Medicare alternative payment model designed to
support people living with dementia and their caregivers. Under
CMS' Guiding an Improved Dementia Experience
(GUIDE) Model, NeuroX will be one of almost 400
participants building Dementia Care Programs (DCPs) across the
country, working to increase care coordination and improve
access to services and supports, including respite care, for people
living with dementia and their caregivers.
"CMS is excited to partner with NeuroX under the GUIDE Model,"
said CMS Administrator Chiquita
Brooks-LaSure. "GUIDE is a new approach to how Medicare will
pay for the care of people living with dementia. The GUIDE
participants are envisioning new ways to support not only people
living with dementia, but also to reduce strain on the people who
care for them, so that more Americans can remain in their homes and
communities, rather than in institutions."
Launched on July 1, 2024, the
GUIDE Model will test a new payment approach for key supportive
services furnished to people living with dementia, including:
comprehensive, person-centered assessments and care plans; care
coordination; 24/7 access to an interdisciplinary care team member
or help line; and certain respite services to support caregivers.
People with dementia and their caregivers will have the assistance
and support of a Care Navigator to help them access clinical and
non-clinical services such as meals and transportation through
community-based organizations.
"We applaud CMS for introducing this comprehensive approach to
enhance care for dementia patients and support their
caregivers," said Dr. Muhammad "Umar" Farooq, Chief
Medical Officer at NeuroX. "Dementia is not merely a disease
affecting an individual; it imposes a significant
socio-economic burden on the entire family. As a physician-led
population health management company, our strategy for
developing a dementia care program under the GUIDE Model is
multifaceted. We are honored to collaborate with CMS to ensure
quality, timely care delivery for those in need."
"GUIDE is the latest innovative CMS value based program focused
on improving clinical quality while lowering health care
expenditures for Medicare," said NeuroX Chief Operating Officer
David Spalding, an industry veteran
with extensive experience in Medicare Shared Savings Program ACOs
and kidney-based value-based care. "As a GUIDE participant, ATP
will deploy our scalable, award winning brain health care
management platform to support our proprietary specialist
telemedicine network and in conjunction with community-based
physician groups focused on senior populations with chronic
conditions."
Dr. Waqas Ahmed, founder and CEO
of NeuroX, adds, "Being selected as a participant in the CMS GUIDE
program marks a significant milestone for NeuroX and underscores
our commitment to. revolutionizing brain health care accessibility.
Our vision has always been aligned with CMS's goal of enhancing
dementia care for patients at home. This opportunity allows us to
further amplify our impact and drive positive change in the lives
of individuals and families affected by neurological
conditions."
NeuroX participation in the GUIDE Model will help people living
with dementia and their caregivers have access to education and
support, such as training programs on best practices for caring for
a loved one living with dementia. The GUIDE Model also provides
respite services for certain people, enabling caregivers to take
temporary breaks from their caregiving responsibilities. Respite is
being tested under the GUIDE Model to assess its effect on helping
caregivers continue to care for their loved ones at home,
preventing or delaying the need for facility care.
GUIDE Participants represent a wide range of health care
providers, including large academic medical centers, small group
practices, community-based organizations, health systems, hospice
agencies, and other practices.
This model delivers on a promise in the Biden Administration's
Executive Order on Increasing Access to High-Quality Care and
Supporting Caregivers and aligns with the National Plan to Address
Alzheimer's Disease. For more information on CMS' GUIDE Model,
please visit:
https://www.cms.gov/priorities/innovation/innovation-models/guide.
About NeuroX:
NeuroX (www.neurox.us) is an award
winning healthcare company dedicated to revolutionizing brain
health through innovative technology and comprehensive care
solutions. By integrating neurology, mental health, and sleep
medicine services under one umbrella, NeuroX delivers value-based
care to patients and families dealing with costly and complex
brain-related health conditions. NeuroX is a division of
American TelePhysicians, founded in 2017 by a team of physicians
and IT professionals under the leadership of Waqas Ahmed, MD FACP. American
TelePhysicians' vision is to transform the global healthcare
industry by incubating customized healthcare ecosystems, and by
bringing affordable medical services to all patients, including
underserved communities. American TelePhysicians achieves this
through various projects, including CURA4U, SmartClinix, and
NeuroX. For more information, visit
www.americantelephysicians.com.
For media inquiries, please contact:
Sherri Johnson
NeuroX
770-265-0728
sherri.johnson@americantelephysicians.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurox-selected-by-centers-for-medicare--medicaid-services-to-test-medicare-dementia-care-model-302191560.html
SOURCE American TelePhysicians